Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens - PubMed (original) (raw)
Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens
Y Kato et al. J Immunol. 2001.
Abstract
Human Vgamma2/Vdelta2(+) gammadelta T cells respond to low molecular-mass nonpeptide Ags in a gammadelta TCR-dependent manner. Although requirements of Ag presentation have remained controversial, we have indicated that specific responses of the primary gammadelta T cells to pamidronate were dependent on monocytic adherent cells for Ag presentation. Here, we show that human tumor cells can efficiently present aminobisphosphonate and pyrophosphomonoester compounds to gammadelta T cells, inducing specific proliferation and IFN-gamma production. gammadelta TCR dependency of the response to Ag-pulsed tumor cells was confirmed by using a Jurkat line transfected with a Vgamma2/Vdelta2 gammadelta TCR. Furthermore, gammadelta T cells exhibited markedly enhanced cytotoxicity against the Ag-pulsed tumor cells as compared with untreated tumor cells. Survey of a number of human tumor cell lines of different origins revealed that the majority of them became susceptible for gammadelta T cell-mediated cytotoxicity following the Ag pulsing except for breast cancer lines so far examined, while normal PHA blast cells remained resistant. The results not only imply a unique mode of nonpeptide Ag recognition by human gammadelta T cells but also may provide a novel strategic clue for immunotherapy of human malignancy.
Similar articles
- Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen.
Miyagawa F, Tanaka Y, Yamashita S, Minato N. Miyagawa F, et al. J Immunol. 2001 May 1;166(9):5508-14. doi: 10.4049/jimmunol.166.9.5508. J Immunol. 2001. PMID: 11313389 - Essential contribution of germline-encoded lysine residues in Jgamma1.2 segment to the recognition of nonpeptide antigens by human gammadelta T cells.
Miyagawa F, Tanaka Y, Yamashita S, Mikami B, Danno K, Uehara M, Minato N. Miyagawa F, et al. J Immunol. 2001 Dec 15;167(12):6773-9. doi: 10.4049/jimmunol.167.12.6773. J Immunol. 2001. PMID: 11739492 - Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate.
Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. Kato Y, et al. J Immunol. 2003 Apr 1;170(7):3608-13. doi: 10.4049/jimmunol.170.7.3608. J Immunol. 2003. PMID: 12646624 - γδ T cells in cancer immunotherapy.
Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L. Zou C, et al. Oncotarget. 2017 Jan 31;8(5):8900-8909. doi: 10.18632/oncotarget.13051. Oncotarget. 2017. PMID: 27823972 Free PMC article. Review. - γδ T cells and their potential for immunotherapy.
Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH, Minato N, Zhang W. Wu YL, et al. Int J Biol Sci. 2014 Jan 10;10(2):119-35. doi: 10.7150/ijbs.7823. eCollection 2014. Int J Biol Sci. 2014. PMID: 24520210 Free PMC article. Review.
Cited by
- Newcastle Disease Virus Virotherapy: Unveiling Oncolytic Efficacy and Immunomodulation.
Zaher KA, Alrahimi JS, Basingab FS, Aldahlawi AM. Zaher KA, et al. Biomedicines. 2024 Jul 5;12(7):1497. doi: 10.3390/biomedicines12071497. Biomedicines. 2024. PMID: 39062070 Free PMC article. - Immunotherapeutic Strategies in the Management of Osteosarcoma.
Supra R, Agrawal DK. Supra R, et al. J Orthop Sports Med. 2023;5(1):32-40. doi: 10.26502/josm.511500076. Epub 2023 Feb 6. J Orthop Sports Med. 2023. PMID: 36937115 Free PMC article. - Reducing farnesyl diphosphate synthase levels activates Vγ9Vδ2 T cells and improves tumor suppression in murine xenograft cancer models.
Liou ML, Lahusen T, Li H, Xiao L, Pauza CD. Liou ML, et al. Front Immunol. 2022 Oct 5;13:1012051. doi: 10.3389/fimmu.2022.1012051. eCollection 2022. Front Immunol. 2022. PMID: 36275712 Free PMC article. - Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T, Yu SK, Xiang Y, Lu KH, Sun M. Yu T, et al. Front Immunol. 2022 Jul 12;13:936496. doi: 10.3389/fimmu.2022.936496. eCollection 2022. Front Immunol. 2022. PMID: 35903099 Free PMC article. Review. - Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions.
Rudge ES, Chan AHY, Leeper FJ. Rudge ES, et al. RSC Med Chem. 2022 Mar 1;13(4):375-391. doi: 10.1039/d1md00297j. eCollection 2022 Apr 20. RSC Med Chem. 2022. PMID: 35647550 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials